Bio Net Receivables vs Current Deferred Revenue Analysis

BIO-B Stock

USD 336.00 3.36 0.99%

Bio Rad financial indicator trend analysis is way more than just evaluating Bio Rad Laboratories prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bio Rad Laboratories is a good investment. Please check the relationship between Bio Rad Net Receivables and its Current Deferred Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Net Receivables vs Current Deferred Revenue

Net Receivables vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bio Rad Laboratories Net Receivables account and Current Deferred Revenue. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Bio Rad's Net Receivables and Current Deferred Revenue is -0.02. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Bio Rad Laboratories, assuming nothing else is changed. The correlation between historical values of Bio Rad's Net Receivables and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Bio Rad Laboratories are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Net Receivables i.e., Bio Rad's Net Receivables and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

-0.02

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Net Receivables

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Bio Rad's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bio Rad Laboratories current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

At present, Bio Rad's Sales General And Administrative To Revenue is projected to increase slightly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 1 B, whereas Selling General Administrative is forecasted to decline to about 475.9 M.

	2021	2022	2023	2024 (projected)
Interest Expense	1.6M	38.1M	49.4M	51.9M
Depreciation And Amortization	176.9M	177.2M	145.9M	153.2M

Interest Expense Depreciation And Amortization

Bio Rad fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Accounts Payable	Intangible Assets	Common Stock	Current Deferred Revenue	Common Stock Total Equity
Total Assets		0.27	0.66	0.51	1.0	0.85	0.14	1.0	0.3	0.99	-0.75	0.71	0.4	0.46	0.97	0.71	0.03	-0.19	0.98	0.69	0.19	-0.12	0.42	-0.37	0.42	0.04
Short Long Term Debt Total	0.27		0.28	-0.03	0.22	0.43	0.95	0.27	-0.08	0.18	0.35	0.81	0.27	0.22	0.47	0.63	0.28	-0.7	0.45	0.76	-0.03	-0.1	0.51	-0.33	0.76	-0.08
Other Current Liab	0.66	0.28		0.42	0.64	0.6	0.12	0.63	0.4	0.64	-0.46	0.51	0.56	0.53	0.68	0.58	0.46	-0.12	0.69	0.59	-0.13	-0.33	0.78	-0.59	0.25	-0.22
Total Current Liabilities	0.51	-0.03	0.42		0.5	0.72	-0.29	0.46	0.85	0.48	-0.56	0.43	0.73	0.78	0.4	0.53	0.38	0.48	0.5	0.5	0.65	0.49	0.39	-0.7	-0.14	0.61
Total Stockholder Equity	1.0	0.22	0.64	0.5		0.83	0.08	1.0	0.3	1.0	-0.78	0.67	0.38	0.44	0.96	0.68	0.0	-0.16	0.97	0.65	0.19	-0.12	0.39	-0.35	0.38	0.04
Property Plant And Equipment Net	0.85	0.43	0.6	0.72	0.83		0.2	0.82	0.55	0.8	-0.5	0.84	0.65	0.78	0.83	0.92	0.29	-0.06	0.88	0.89	0.36	0.27	0.48	-0.72	0.46	0.25
Net Debt	0.14	0.95	0.12	-0.29	0.08	0.2		0.15	-0.38	0.06	0.46	0.64	0.05	-0.04	0.35	0.44	0.17	-0.81	0.3	0.57	-0.16	-0.24	0.38	-0.07	0.75	-0.21
Retained Earnings	1.0	0.27	0.63	0.46	1.0	0.82	0.15		0.25	0.99	-0.74	0.69	0.34	0.4	0.97	0.67	-0.01	-0.23	0.97	0.67	0.19	-0.17	0.39	-0.31	0.44	0.04
Cash	0.3	-0.08	0.4	0.85	0.3	0.55	-0.38	0.25		0.27	-0.41	0.32	0.71	0.76	0.21	0.42	0.35	0.54	0.31	0.39	0.42	0.47	0.37	-0.73	-0.25	0.41
Non Current Assets Total	0.99	0.18	0.64	0.48	1.0	0.8	0.06	0.99	0.27		-0.79	0.63	0.33	0.39	0.95	0.63	-0.04	-0.16	0.95	0.61	0.18	-0.16	0.36	-0.3	0.37	0.04
Non Currrent Assets Other	-0.75	0.35	-0.46	-0.56	-0.78	-0.5	0.46	-0.74	-0.41	-0.79		-0.2	-0.3	-0.33	-0.61	-0.24	0.07	-0.39	-0.64	-0.2	-0.2	0.04	-0.19	0.19	0.27	-0.11
Cash And Short Term Investments	0.71	0.81	0.51	0.43	0.67	0.84	0.64	0.69	0.32	0.63	-0.2		0.55	0.57	0.81	0.89	0.26	-0.39	0.82	0.97	0.2	0.07	0.59	-0.58	0.62	0.1
Net Receivables	0.4	0.27	0.56	0.73	0.38	0.65	0.05	0.34	0.71	0.33	-0.3	0.55		0.88	0.4	0.71	0.76	0.32	0.46	0.67	0.05	0.47	0.76	-0.88	-0.02	0.03
Common Stock Shares Outstanding	0.46	0.22	0.53	0.78	0.44	0.78	-0.04	0.4	0.76	0.39	-0.33	0.57	0.88		0.42	0.8	0.64	0.39	0.5	0.72	0.17	0.61	0.54	-0.97	0.04	0.14
Non Current Liabilities Total	0.97	0.47	0.68	0.4	0.96	0.83	0.35	0.97	0.21	0.95	-0.61	0.81	0.4	0.42		0.76	0.07	-0.35	0.99	0.78	0.1	-0.2	0.51	-0.37	0.54	-0.05
Inventory	0.71	0.63	0.58	0.53	0.68	0.92	0.44	0.67	0.42	0.63	-0.24	0.89	0.71	0.8	0.76		0.46	-0.18	0.79	0.97	0.11	0.3	0.57	-0.78	0.57	0.02
Other Current Assets	0.03	0.28	0.46	0.38	0.0	0.29	0.17	-0.01	0.35	-0.04	0.07	0.26	0.76	0.64	0.07	0.46		0.2	0.11	0.43	-0.14	0.27	0.63	-0.7	-0.03	-0.11
Other Stockholder Equity	-0.19	-0.7	-0.12	0.48	-0.16	-0.06	-0.81	-0.23	0.54	-0.16	-0.39	-0.39	0.32	0.39	-0.35	-0.18	0.2		-0.28	-0.28	0.17	0.59	-0.14	-0.29	-0.86	0.25
Total Liab	0.98	0.45	0.69	0.5	0.97	0.88	0.3	0.97	0.31	0.95	-0.64	0.82	0.46	0.5	0.99	0.79	0.11	-0.28		0.81	0.18	-0.12	0.52	-0.45	0.5	0.04
Total Current Assets	0.69	0.76	0.59	0.5	0.65	0.89	0.57	0.67	0.39	0.61	-0.2	0.97	0.67	0.72	0.78	0.97	0.43	-0.28	0.81		0.15	0.18	0.64	-0.73	0.59	0.05
Short Term Debt	0.19	-0.03	-0.13	0.65	0.19	0.36	-0.16	0.19	0.42	0.18	-0.2	0.2	0.05	0.17	0.1	0.11	-0.14	0.17	0.18	0.15		0.29	-0.17	-0.09	-0.02	0.99
Accounts Payable	-0.12	-0.1	-0.33	0.49	-0.12	0.27	-0.24	-0.17	0.47	-0.16	0.04	0.07	0.47	0.61	-0.2	0.3	0.27	0.59	-0.12	0.18	0.29		-0.13	-0.52	-0.22	0.35
Intangible Assets	0.42	0.51	0.78	0.39	0.39	0.48	0.38	0.39	0.37	0.36	-0.19	0.59	0.76	0.54	0.51	0.57	0.63	-0.14	0.52	0.64	-0.17	-0.13		-0.64	0.21	-0.23
Common Stock	-0.37	-0.33	-0.59	-0.7	-0.35	-0.72	-0.07	-0.31	-0.73	-0.3	0.19	-0.58	-0.88	-0.97	-0.37	-0.78	-0.7	-0.29	-0.45	-0.73	-0.09	-0.52	-0.64		-0.1	-0.07
Current Deferred Revenue	0.42	0.76	0.25	-0.14	0.38	0.46	0.75	0.44	-0.25	0.37	0.27	0.62	-0.02	0.04	0.54	0.57	-0.03	-0.86	0.5	0.59	-0.02	-0.22	0.21	-0.1		-0.1
Common Stock Total Equity	0.04	-0.08	-0.22	0.61	0.04	0.25	-0.21	0.04	0.41	0.04	-0.11	0.1	0.03	0.14	-0.05	0.02	-0.11	0.25	0.04	0.05	0.99	0.35	-0.23	-0.07	-0.1

Click cells to compare fundamentals

Bio Rad Account Relationship Matchups

Bio Rad fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	8.0B	13.0B	17.8B	13.5B	12.3B	12.9B
Short Long Term Debt Total	439.8M	14.1M	11.0M	1.2B	1.4B	1.5B
Other Current Liab	158.5M	354.0M	404.9M	312.2M	302.0M	317.1M
Total Current Liabilities	905.5M	631.5M	680.9M	568.7M	522.8M	338.4M
Total Stockholder Equity	5.8B	9.9B	13.7B	9.6B	8.7B	9.2B
Property Plant And Equipment Net	701.2M	693.5M	695.8M	679.6M	723.7M	759.9M
Net Debt	(220.9M)	(648.1M)	(459.8M)	764.0M	1.0B	1.1B
Retained Earnings	5.5B	9.3B	13.5B	9.9B	9.3B	9.7B
Cash	660.7M	662.2M	470.8M	434.2M	404.0M	257.1M
Non Current Assets Total	5.8B	10.8B	15.8B	10.3B	9.3B	9.7B
Non Currrent Assets Other	(997.7B)	(2.1T)	(3.1T)	(1.8T)	96.4M	101.2M
Cash And Short Term Investments	1.1B	996.7M	875.5M	1.8B	1.6B	1.7B
Net Receivables	392.7M	419.4M	423.5M	494.6M	489.0M	272.4M
Common Stock Shares Outstanding	30.2M	30.2M	30.2M	29.8M	29.2M	29.1M
Liabilities And Stockholders Equity	8.0B	13.0B	17.8B	13.5B	12.3B	12.9B
Non Current Liabilities Total	1.3B	2.5B	3.4B	3.3B	3.0B	3.2B
Inventory	554.0M	622.3M	572.2M	719.3M	780.5M	819.5M
Other Current Assets	113.3M	97.5M	124.8M	153.3M	171.7M	92.3M
Other Stockholder Equity	371.6M	329.5M	335.4M	183.9M	(183.5M)	(174.3M)
Total Liab	2.3B	3.1B	4.1B	3.9B	3.6B	3.7B
Total Current Assets	2.2B	2.1B	2.0B	3.2B	3.0B	3.2B
Accumulated Other Comprehensive Income	(87.3M)	282.5M	(175.6M)	(466.8M)	(336.0M)	(319.2M)
Short Term Debt	426.2M	38.3M	36.9M	36.8M	40.4M	33.9M
Accounts Payable	287.1M	139.5M	141.9M	135.0M	144.6M	116.6M
Intangible Assets	145.5M	199.5M	253.9M	332.1M	320.5M	188.7M
Current Deferred Revenue	33.7M	42.5M	50.9M	52.2M	35.8B	37.5B
Property Plant And Equipment Gross	1.4T	693.5M	1.5B	1.5B	1.8B	1.7B
Short Term Investments	459.5M	334.5M	404.7M	1.4B	1.2B	1.3B
Good Will	264.1M	291.9M	347.3M	406.5M	413.6M	419.6M
Net Tangible Assets	5.3B	9.9B	13.3B	9.2B	10.6B	5.4B
Long Term Debt	13.6M	12.3M	10.5M	1.2B	1.2B	1.3B
Retained Earnings Total Equity	5.5B	9.3B	13.5B	9.9B	11.4B	12.0B
Long Term Debt Total	13.6M	12.3M	10.5M	1.2B	1.1B	1.1B
Capital Surpluse	410.0M	429.4M	441.7M	447.5M	514.6M	384.1M
Deferred Long Term Liab	997.8M	2.1B	3.1B	1.8B	2.0B	2.1B
Treasury Stock	(38.4M)	(99.9M)	(106.3M)	(263.6M)	(237.2M)	(225.4M)
Non Current Liabilities Other	160.9M	372.1M	358.1M	349.5M	195.1M	216.0M
Accumulated Depreciation	(882.8M)	(961.4M)	(997.6M)	(1.0B)	(908.5M)	(953.9M)
Property Plant Equipment	701.2M	491.4M	491.0M	498.6M	573.4M	538.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether Bio Rad Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Rad's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Rad Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Rad Laboratories Stock:

How To Invest In Bio

Details

Is Bio Stock a good investment?

Details

What is Bio Rad's Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Please note, there is a significant difference between Bio Rad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Rad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Rad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bio Net Receivables vs Current Deferred Revenue Analysis

Net Receivables vs Current Deferred Revenue

Net Receivables vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Net Receivables

Current Deferred Revenue

Bio Rad fundamental ratios Correlations

Bio Rad Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bio Rad fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Retained Earnings	+ 1.0	Total Assets
Retained Earnings	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Retained Earnings

Common Stock	- 0.97	Common Stock Shares Outstanding
Common Stock	- 0.88	Net Receivables
Current Deferred Revenue	- 0.86	Other Stockholder Equity
Other Stockholder Equity	- 0.81	Net Debt
Non Currrent Assets Other	- 0.79	Non Current Assets Total
Common Stock	- 0.78	Inventory